Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

This study is testing whether canagliflozin — a diabetes drug that affects how the kidneys and cells handle sugar — can reduce fluid retention problems and internal scarring (fibrosis) in people with kidney failure who are on peritoneal dialysis (a type of home-based dialysis). **You may be eligible if...** - You are an adult with kidney failure on peritoneal dialysis - You have been on a stable dialysis prescription using dextrose-based dialysis fluid for at least 3 months - You are classified as a "high" or "high-average" transporter based on a peritoneal function test **You may NOT be eligible if...** - You have a history of diabetic ketoacidosis without high blood sugar (euglycemic DKA) - You have a known allergy to canagliflozin - You have active peritoneal infection or tunnel infection - You are scheduled for a kidney transplant within 6 months - You have severe liver disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.